Evidence map›Paper›PMID 36199494›Full record

ArticleJournal of the advanced practitioner in oncology2022

Timely Genetic Testing and Therapy Management in Patients With g

Ashley Martinez, Tiffany Jones, Joanne C Ryan, Chad M Barnett, Elpitha L Soussou, Sarah Donahue

Open access · greenAbstract read
In one paragraph

Article in Journal of the advanced practitioner in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ashley MartinezThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Tiffany JonesOHC/US Oncology Blue Ash, Cincinnati, Ohio.
Joanne C RyanPfizer Inc., New York, New York.
Chad M BarnettPfizer Inc., New York, New York.
Elpitha L SoussouPfizer Inc., New York, New York.
Sarah DonahueUniversity of California San Francisco.
Pfizer (United States) · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that has demonstrated strong efficacy with manageable side effects for patients with germline breast cancer susceptibility genes 1 or 2 (g

Identifiers

PMID36199494
PMCPMC9514123
OpenAlexW4297513933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.